Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Lai calls on int'l community to unite against China ethnic unity law
08/04/2026 01:02 PM - Business
TSMC's Kumamoto fab back to normal after earthquake
08/04/2026 12:25 PM - Culture
Taiwan wins 2 silver, 4 bronze at International Linguistics Olympiad
08/04/2026 12:10 PM - Business
Rules on cooling period for disposition stocks eased
08/04/2026 12:00 PM - Politics
Palau appoints Taiwanese scholar as health minister's special adviser
08/04/2026 11:17 AM